ReviewInternational journal of hematology2026
Biomarker-driven strategies and challenges in acute graft-versus-host disease clinical trials.
Review in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation. Traditional risk stratification based on clinical symptoms provides only modest prognostic accuracy for treatment response and long-term outcomes. Several biomarkers have shown promise in improving predictive and prognostic precision. Biomarker-guided strategies can identify high-risk patients before extensive target organ damage occurs and low-risk patients who may benefit from lower-intensity treatment, thereby reducing GVHD-related organ injury and adverse effects such as infection and disease relapse. These approaches have facilitated more personalized treatment, with some studies reporting reduced infection rates and improved GVHD-related outcomes in appropriately selected populations. Biomarker-driven clinical trial designs represent a promising framework for developing risk-adapted GVHD management strategies; however, continued validation and refinement of biomarker algorithms is essential to optimize patient outcomes.
Indexed as
Identifiers
41389175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.